摘要:
Compounds of formula I: ##STR1## as well as tautomers, pharmaceutically acceptable salts, hydrates, prodrugs and reduced forms are disclosed. The compounds are useful for the treatment and prevention of diabetes mellitus, and in particular, for the treatment or prevention of hyperglycemia in diabetic patients.
摘要:
Indoles of Formula I having —X-aryl-(CH2)x-oxazolidinedione and —X-heteroaryl-(CH2)x-oxazolidinedione substituents on the N atom of the indole ring, where x is 0 or 1, and —X— is a bond or —CH2—, and their thiazolidinedione analogs, are PPAR gamma agonists or partial agonists and are useful in the treatment and control of type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.
摘要:
Indoles of Formula I having —X-aryl-(CH2)x-oxazolidinedione and —X-heteroaryl-(CH2)x-oxazolidinedione substituents on the N atom of the indole ring, where x is 0 or 1, and —X— is a bond or —CH2—, and their thiazolidinedione analogs, are PPAR gamma agonists or partial agonists and are useful in the treatment and control of type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.
摘要:
Indoles having aryloxyalkanoic acid substituents or arylalkanoic acid substituents are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.
摘要:
Indoles having aryloxyalkanoic acid substituents or arylalkanoic acid substituents are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.
摘要:
Disclosed herein are substituted imidazopyridine compounds of formula (I) which are inhibitors of indoleamine 2,3-dioxygenase (IDO) and/or tryptophan-2,3-dioxygenase (TDO) enzymes: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder.
摘要:
Various embodiments of the present disclosure provide improved systems and techniques for intelligently allocating cache requests to caches based upon the nature of the cache objects associated with the cache requests, and/or the condition of the caches in the distributed cache system, to facilitate cache system utilization and performance. In some embodiments, an allocation of cache requests may be performed in response to detection of a problem at one of a group of cache servers. For example, in some embodiments, a particular cache server may be entered into a safe mode of operations when the cache's ability to service cache requests is impaired. In other embodiments, an allocation of cache requests may be performed based on an cache object data type associated with the cache requests.
摘要:
A method for transmitting control signaling, an apparatus for processing control signaling and a terminal are provided. A base station transmits evolved control signaling to an evolved terminal on M downlink subframes in a radio frame, wherein M is an integer greater than or equal to 1 and less than N, and N is the number of the downlink subframes in the radio frame. The above technical solution enhances basic control signaling of an LTE-series standard, reduces system overhead and terminal energy consumption, meets demands for future development of the industry, solves the problem of large system overhead and high terminal energy consumption due to the wireless communication standards, and meanwhile also gives sufficient consideration to backward compatibility of the system, and better meets demands of data users rapidly developing and future development of the wireless communications industry.
摘要:
The invention provides a power divider, comprising: a plurality of transmission stages and a plurality of ground layers alternately arranged on respective ones of a plurality of dielectric layers, a first transmission stage being arranged on a first dielectric layer, and a last transmission stage being arranged below a last dielectric layer; wherein the plurality of transmission stages are arrayed vertically, each consisting of a loop formed by a transmission line; the first transmission stage has a first opening connected by a resistor, and each of the remaining transmission stages has the first opening connected by the resistor and a second opening without a resistor; two ends of the first opening of one of the adjacent transmission stages are connected to two ends of the second opening of the other one of the adjacent transmission stages by via transitions, in a top-to-bottom direction; and each ground layer has clearances through which the via transitions pass. The invention also provides a method of fabricating the power divider.
摘要:
The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.